"Prope" tolerance: Induction, lymphocyte depletion with minimal maintenance

Transplantation

Volumn 80, Issue 1, 2005, Pages 6-7

  Calne, Roy ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Douglas House Annex ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; TACROLIMUS; THYMOCYTE ANTIBODY;

GRAFT REJECTION; HEPATITIS C; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; NOTE; PRIORITY JOURNAL; VIRUS REACTIVATION;

HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; MAJOR HISTOCOMPATIBILITY COMPLEX; TRANSPLANTATION TOLERANCE;

EID: 22144470149     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000164351.72220.1A     Document Type: Note

References (5)

1. Buhler, LH, Spitzer TR, Sykes M, et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002; 74: 1405.
2. Calne RY Calne RY, Friend PJ, et al. Prope tolerance, perioperative Campath IH, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 1998; 351: 1701.
3. Watson CJE, Firth J, Bradley JR, et al. Campath 1H (Alemtuzumab) in renal transplantation: 5-year comparative follow up [Abstract 0143]. From the Proceedings of the XX International Congress Transplantation Society, Vienna, Austria, 2004.
4. Surh CD, Sprent J. Homeostatic T cell proliferation: how far can T cells be activated to self-ligands? J Exp Med 2000; 192: F9.
5. Shapiro R, Basu A, Tan HP, Khan AS, et al. Campath preconditioning and tacrolimus monotherapy with subsequent weaning in renal transplant recipients. From the Proceedings of the XX International Congress Transplantation Society, Vienna, Austria, 2004.